Algert Global LLC Buys Shares of 58,848 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Algert Global LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 58,848 shares of the company's stock, valued at approximately $886,000. Algert Global LLC owned about 0.13% of Pacira BioSciences at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in PCRX. Vanguard Group Inc. increased its position in shares of Pacira BioSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock worth $149,413,000 after acquiring an additional 14,960 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Pacira BioSciences by 6.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 39,229 shares of the company's stock worth $1,145,000 after acquiring an additional 2,455 shares in the last quarter. Jane Street Group LLC increased its position in shares of Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company's stock worth $5,480,000 after acquiring an additional 177,557 shares in the last quarter. Park Place Capital Corp purchased a new position in shares of Pacira BioSciences in the second quarter worth approximately $46,000. Finally, GAMMA Investing LLC increased its position in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock worth $38,000 after acquiring an additional 932 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Raymond James downgraded shares of Pacira BioSciences from an "outperform" rating to a "market perform" rating in a research report on Monday, August 12th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. JPMorgan Chase & Co. restated an "underweight" rating and set a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. Finally, HC Wainwright decreased their price target on shares of Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a report on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $23.50.

Pacira BioSciences Stock Up 1.6 %

NASDAQ PCRX traded up $0.27 during trading on Friday, reaching $16.91. The company's stock had a trading volume of 296,431 shares, compared to its average volume of 844,038. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95. The stock has a market capitalization of $780.79 million, a PE ratio of -8.33 and a beta of 0.82. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $16.46 and a 200-day moving average price of $19.91.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.